Image

The Eswatini PRISM Study on Adolescents Living With HIV

The Eswatini PRISM Study on Adolescents Living With HIV

Recruiting
10-19 years
All
Phase N/A

Powered by AI

Overview

Adolescents living with Human Immunodeficiency Virus (ALHIV) are at an increased risk of experiencing psychological distress and adverse mental health outcomes, particularly in low- to middle-income countries (LMICs). Although interventions aimed at promoting resilience have demonstrated potential in enhancing psychosocial outcomes among adolescents with chronic illnesses in high-income settings, there is a paucity of evidence from LMICs. This study protocol aims to outline a comprehensive framework for evaluating the feasibility, acceptability, and effectiveness of the Promoting Resilience in Stress Management (PRISM) intervention in comparison to standard psychosocial care among ALHIV in a LMIC, such as Eswatini (formerly known as Swaziland). Additionally, it seeks to gather qualitative insights from both participants and PRISM coaches regarding the PRISM program. Exploratory outcomes under investigation are psychological distress, resilience, and HIV health-related quality of life. We hypothesise that:

  1. Participants in the PRISM intervention group will experience reduced psychological distress compared to those in the control arm.
  2. Participants in the PRISM intervention group will report improved HIV health-related quality of life after receiving the intervention compared to the control group.
  3. Participants in the intervention arm will have higher resilience scores after receiving the intervention compared to those receiving usual psychosocial care.

Description

This study employs an explanatory sequential mixed-methods design to rigorously evaluate the Promoting Resilience in Stress Management (PRISM) intervention. In the initial quantitative phase, a single-site, single-blind, pilot randomized controlled trial (RCT) will be conducted. A sample of (n=140) ALHIV will be recruited and randomly assigned to either the PRISM intervention arm or a control arm receiving standard psychosocial care. The PRISM intervention, a manualized, skills-based training program, originally comprises six 30-60-minute, one-on-one sessions designed to enhance resilience resources, including stress management, goal-setting, cognitive reframing, and meaning-making, in adolescents and young adults (AYAs). For the purposes of this trial, the PRISM intervention will be adapted to consist of three 60-minute sessions, delivered at intervals of 1-2 weeks based on participant preference. Participants in both arms will complete validated survey instruments to assess exploratory outcomes, including psychological distress, resilience, and HIV-related quality of life. Data collection will occur at baseline (T0), and at 3 months (T1), 6 months (T2), 9 months (T3), and 12 months (T4) post-enrollment. The researchers will then evaluate the feasibility, acceptability, and effectiveness of the PRISM intervention based on these outcomes.

In the second phase of the study, an Exploratory-Descriptive Qualitative (EDQ) research design will be employed to investigate the experiences and perceptions of participants engaged in the PRISM program. Data collection will involve the use of semi-structured interview guides administered to nurse PRISM coaches and a purposively selected sample of ALHIV from the intervention arm of the pilot clinical trial. The collected data will undergo rigorous thematic analysis to elucidate key insights into the participants' experiences and perceptions of the PRISM intervention, thereby contributing to a deeper understanding of its implementation and impact.

Eligibility

Inclusion Criteria for the Clinical Trial:

  • Adolescents living with HIV aged 10-19 years.
  • Adolescents living with HIV who are cognitively able to participate in interviews (based on their medical history).
  • Adolescents living with HIV who will have a score \> 13 on the Kessler Screening Scale for Psychological Distress (K6).

Exclusion Criteria for the Clinical Trial:

  • Adolescents who refuse to participate.
  • Adolescents whose parents/caretakers (for \<18 years) will not consent to their participation.
  • Adolescents who will report having suicidal thoughts (i.e., who will respond yes to one item asking if they thought of killing themselves in the last 30days). This exclusion is based on the understanding that the PRISM intervention was not designed to address suicidal ideation, as confirmed by its developers. Such individuals will be referred to a licensed psychologist following the study's established referral plan, thereby ensuring they receive the appropriate care and support.

Inclusion criteria for a support person:

The PRISM intervention requires a caretaker or parent to be invited by the study participant to join the third session.

• Parent or caretaker should be ≥ 18 years of age and consent to participation.

Exclusion criteria for a support person:

• A parent or caretaker who refuses to participate.

Eligibility Criteria for Participation in Semi-Structured Interviews Post Intervention

Inclusion criteria for participants:

  • Adolescents who have been in the treatment arm of the PRISM intervention pilot clinical trial.
  • Adolescents who completed all sessions of the PRISM intervention.
  • Adolescents who are willing to be audio taped.

Exclusion criteria for participants:

• Participants who meet the inclusion criteria but are unwilling to provide informed consent or assent and/or parental consent.

Inclusion criteria for implementers:

• PRISM coaches who offered all sessions of the PRISM intervention and who will be willing to be audio-taped.

Exclusion criteria for implementers:

• PRISM coaches who meet the inclusion criteria but are unwilling to provide informed consent to participate.

Study details
    Human Immunodeficiency Virus
    Psychological Stress

NCT07101458

Eswatini Nazarene Health Institutions

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.